India to Kenya: Rituximab Export Trade Route

The India to Kenya Rituximab corridor is one of India's established pharmaceutical export routes, with 211 shipments documented worth a combined $657.9K USD. The route is dominated by DR.REDDY'S LABORATORIES LTD, which alone accounts for roughly 39% of all export value, reflecting the consolidated nature of India's rituximab manufacturing sector.

Across 27 active suppliers, the average shipment value stands at $3.1K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 78% of all shipments, consistent with rituximab's non-urgent bulk-order profile.

Shipment activity peaks during October–December, with an average transit time of 28 days port-to-port. The route has recorded an annual growth rate of 29.3%, placing it at rank #14 among India's top rituximab export destinations globally.

On the import side, key buyers of Indian rituximab in Kenya include NA, TO, AS PER INVOICE AS and 41 others. NA is the single largest importer with 11 shipments valued at $271.6K USD.

India's rituximab exports to Kenya are driven primarily by a handful of large-scale manufacturers. DR.REDDY'S LABORATORIES LTD with 2 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 27 active exporters signals a competitive but concentrated market — buyers in Kenya benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — DR.REDDY'S LABORATORIES LTD, R.S. SURGIPHARM PRIVATE LIMITED, PLASMA LIFE CARE — together account for 59% of total trade value on this route. The average shipment value of $3.1K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as rituximab injection 100mg(ituxredi 100)(qty:1000 vials) and (harmless medicines for injectableand capsules and tablets)rituximab injection 500mg/50ml(1 vial), suggesting that buyers in Kenya tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, NA is the largest importer with 11 shipments worth $271.6K USD — representing 41% of all rituximab imports from India on this route. A total of 44 buyers are active on this corridor.